Harvard Apparatus Regenerative Technology, Inc.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
HRGNStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Nine Months Ended | ||
|---|---|---|
| September 30, | ||
| 2025 | 2024 | |
| OPERATING ACTIVITIES | ||
| Net loss | $(5,182) | $(6,388) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Share-based compensation expense | 1,517 | 1,694 |
| Depreciation | 4 | 12 |
| Amortization of operating lease right-of-use assets | 72 | 128 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 228 | 3 |
| Inventory | 58 | (63) |
| Prepaid research and development | 37 | 89 |
| Prepaid expenses and other current assets | 117 | (59) |
| Deferred financing costs | — | 544 |
| Long-term prepaid contracts | 213 | 208 |
| Accounts payable | (139) | 62 |
| Operating lease liability | (70) | (117) |
| Accrued and other current liabilities | 106 | 160 |
| Deferred revenue | 128 | — |
| Insurance premium financing payable | (253) | — |
| Net cash used in operating activities | (3,164) | (3,727) |
| FINANCING ACTIVITIES | ||
| Proceeds from convertible debt – related party | — | 500 |
| Proceeds from issuance of common stock | 2,000 | 6,482 |
| Proceeds from exercise of warrants | — | 430 |
| Payments on convertible debt - related party | — | (500) |
| Net cash provided by financing activities | 2,000 | 6,912 |
| Effect of exchange rate changes on cash | (3) | (24) |
| Net decrease in cash and cash equivalents | (1,167) | 3,161 |
| Cash and cash equivalents at the beginning of the year | 2,486 | 432 |
| Cash and cash equivalents at the end of the period | $1,319 | $3,593 |
| SUPPLEMENTAL INFORMATION | ||
| Interest paid in cash | $7 | $36 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.